Chandra Bhagat Pharma AGM resolutions pass unanimously with 100% support
- All four AGM resolutions passed unanimously with 100% support from polled votes
- Promoters held 5.5 million shares (73%) and voted fully in favor
- Only eight shareholders attended the physical meeting in Mumbai
- Issuance of 66 lakh convertible warrants approved on preferential basis
*this image is generated using AI for illustrative purposes only.
Chandra Bhagat Pharma shareholders approved all four agenda items at its 23rd Annual General Meeting on September 1, 2026. The resolutions received 100% support from the votes polled, with no dissent recorded.
The meeting, chaired by Managing Director Hemant Chandravadan Bhagat, took place at the company’s office in Matunga (East), Mumbai. The ordinary business items included the adoption of annual accounts for FY26 and the re-appointment of director Pranav Hemant Bhagat. Special business resolutions focused on increasing authorized share capital and issuing up to 66,00,000 convertible warrants on a preferential basis.
Voting Participation
Voting was conducted via physical polling papers, as the company is listed on the BSE SME Platform and exempt from e-voting requirements under the MCA Notification dated March 19, 2015. The cut-off date for voting eligibility was August 25, 2026.
| Category | Shares Held | Votes Polled | % Polled | In Favor | Against |
|---|---|---|---|---|---|
| Promoters | 5,509,056 | 4,579,264 | 83.12% | 4,579,264 | 0 |
| Public Non-Institutions | 2,036,000 | 2,000 | 0.10% | 2,000 | 0 |
| Total | 7,545,056 | 4,581,264 | 60.72% | 4,581,264 | 0 |
Only eight shareholders attended the meeting: six from the promoter group and two from the public category. No shareholders participated via video conferencing or e-voting.
Audit and Compliance
The statutory auditors issued an unqualified report for FY26, with no qualifications or observations noted for the year ended March 31, 2026. The Chairman confirmed that the requisite quorum was present to validate the proceedings. The scrutinizer’s report, filed by Amit Dharmani & Associates, confirmed that all resolutions were passed with the requisite majority.
What the Numbers Show
Promoter dominance was evident in the voting dynamics. The promoter group holds 5,509,056 shares, representing approximately 73% of the total outstanding equity of 7,545,056 shares. With promoters casting 100% of their polled votes in favor, the outcome of the special resolutions—particularly the issuance of convertible warrants—was effectively determined by the controlling stake. Public participation remained negligible, with only 2,000 votes cast by non-institutional public shareholders against a holding base of over 2 million shares.
Historical Stock Returns for Chandra Bhagat Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -0.10% | 0.0% | +64.94% | 0.0% | -63.35% |
What specific strategic initiatives or projects is Chandra Bhagat Pharma planning to fund with the proceeds from the issuance of 660,000 convertible warrants?
How might the increase in authorized share capital impact the current promoter holding percentage and control structure upon the eventual conversion of these warrants?
Given the negligible public participation (0.10%) in the AGM, what measures does management plan to implement to improve retail shareholder engagement and transparency?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
